Aligos Therapeutics (ALGS) Jefferies London Healthcare Conference 2025 summary

Portfolio overview and pipeline updates

• Lead program pevifoscorvir (pevi) targets hepatitis B, showing strong phase II progress and unique dual mechanisms of action.

• Additional assets include ALG-009 (beta thyroid agonist for MASH), a pan-coronavirus protease inhibitor in phase II, and preclinical antisense oligonucleotides for HBV and HDV.

• Pevi is the first capsid assembly modulator in the clinic to demonstrate effects on cccDNA, a key viral reservoir.

• Phase II global study of pevi is ongoing, with interim analysis expected early next year and top-line data in 2027.

• ALG-009 shows superior potency and pharmacokinetics compared to competitors, with phase II-B readiness and potential for accelerated development.

Clinical results and competitive positioning

• Pevi monotherapy achieves rapid and sustained HBV DNA suppression, outperforming standard nucleoside analogs in both E positive and E negative patients.

• No drug resistance observed with pevi, even against variants resistant to other capsid assembly modulators, enabling monotherapy and regulatory alignment.

• Pevi reduces HBV surface and E antigens, indicating cccDNA suppression; antigen reductions are maintained after therapy cessation.

• Safety profile is favorable, with no discontinuations due to adverse events and only transient ALT elevations.

• Pevi is positioned as a future standard of care for chronic HBV suppression and as a combination partner for functional cure regimens.

Market need and future milestones

• Chronic HBV remains a major global health issue, with current therapies leaving most patients at risk for liver disease and cancer.

• Pevi addresses the unmet need for broader and deeper viral suppression, especially for patients ineligible for functional cure therapies.

• Upcoming milestones include interim phase II analysis (early next year) and primary endpoint readout in 2027.

• ALG-009 demonstrated nearly double the fat reduction of a leading competitor in MASH and may enhance weight loss when combined with incretins.

• Full data on ALG-009’s metabolic effects to be presented at an upcoming Hep-DART meeting.